HK-listed pharmaceutical product maker YiChang hit 6-week high on drug update

Yichang Hec Changjiang Pharmaceutical Co

09/06/2020 04:05

** Shares of YiChang HEC ChangJiang Pharmaceutical Co Ltd
 1558.HK  surge as much as 13.7% to HK$16.02, the highest since
April 28 
    ** Stock heads for biggest intraday pct gain since Jan. 20
    ** Chinese pharmaceutical products maker says application
for production of its Recombinant Human Insulin Injection
product is pending approval from the National Medical Products
Administration (NMPA) (https://bit.ly/30jApsN)
    ** Co says it will disclose the drug information, progress
stage and market conditions of the product after obtaining the
relevant official documents issued by NMPA
    ** As of last close, the stock had fallen 35.6% so far this
year
    ** Hubei-based YiChang HEC has underperformed the Hang Seng
Commerce & Industry Index sector  .HSNC  by 6.7 percentage
points in the past one month
    ** Both the Hang Seng China enterprises index  .HSCE  and
the benchmark index  .HSI  rise 1.1%

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)